MK-677 (Ibutamoren)
Quick summary
An orally active, non-peptide ghrelin-receptor agonist studied for sustained growth-hormone and IGF-1 release. Research focus: ghrelin receptor agonism and GH/IGF-1 axis. SRP's starting dose for this compound is still pending.
3D structure
Overview
An orally active, non-peptide ghrelin-receptor agonist studied for sustained growth-hormone and IGF-1 release.
Looking for research material? Simple Research Peptides lists MK-677 12.5 mg Capsules – 60 Count for laboratory research use.
Mechanism
An oral, non-peptide ghrelin-receptor agonist that raises growth hormone and IGF-1 over sustained periods.
Research areas
- ghrelin receptor agonism
- GH/IGF-1 axis
Storage & reconstitution
Supplied in capsule form. Store sealed in a cool, dry place away from light and moisture.
Recommended starting dose (low and slow)
| Starting dose | Pending - to be added by SRP |
|---|---|
| Frequency | Once daily (oral). |
| Reconstitution | Pending - to be added by SRP |
Route and timing
Route: Oral.
Timing: Pending - to be added by SRP
Cycle length and repeat
Pending - to be added by SRP
Half-life
Approximate, for Bobby's review: About 4 to 6 hours (oral), with effects that last longer.
Side effects
Pending - to be added by SRP
Suggested bloodwork and monitoring
Draft, for Bobby's review: CBC and comprehensive metabolic panel (kidney and liver function, electrolytes) before starting and again after a few weeks; IGF-1, fasting glucose and HbA1c.
Cautions
Pending - to be added by SRP
Reconstitution calculator
Math aid only. It converts the numbers you enter; it is not dosing advice. For research use only.
Frequently asked questions
What is MK-677 (Ibutamoren) studied for?
In research it is studied for ghrelin receptor agonism and GH/IGF-1 axis. An oral, non-peptide ghrelin-receptor agonist that raises growth hormone and IGF-1 over sustained periods.
How is MK-677 (Ibutamoren) given in research?
Oral. See the dosing frequency block on this page for how often.
What amount should a researcher start with?
SRP has not yet published a starting dose for MK-677 (Ibutamoren). Contact SRP before starting any research protocol, and do not guess.
Related peptides
Last updated: October 19, 2026